Literature DB >> 20096781

Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.

Sylvia Navailles1, Bernard Bioulac, Christian Gross, Philippe De Deurwaerdère.   

Abstract

Benefit and motor side effects of l-DOPA in Parkinson's disease have been related to dopamine transmission in the striatum. However, the putative involvement of serotonergic neurons in the dopaminergic effects of l-DOPA suggests that the striatum is not a preferential target of l-DOPA. By using microdialysis in a rat model of Parkinson's disease, we found that l-DOPA (3-100 mg/kg) increased dopamine extracellular levels monitored simultaneously in four brain regions receiving serotonergic innervation: striatum, substantia nigra, hippocampus, prefrontal cortex. The increase was regionally similar at the lowest dose and 2-3 times stronger in the striatum at higher doses. Citalopram, a serotonin reuptake blocker, or the destruction of serotonergic fibers by 5,7-dihydroxytryptamine impaired l-DOPA-induced dopamine release in all regions. These data demonstrate that l-DOPA induces an ectopic release of dopamine due to serotonergic neurons. The new pattern of dopamine transmission created by l-DOPA may contribute to the benefit and side effects of l-DOPA. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096781     DOI: 10.1016/j.nbd.2010.01.012

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  60 in total

1.  Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.

Authors:  Corinne Y Ostock; Kristin B Dupre; Karen L Eskow Jaunarajs; Hannah Walters; Jessica George; David Krolewski; Paul D Walker; Christopher Bishop
Journal:  Neuropharmacology       Date:  2011-05-27       Impact factor: 5.250

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

3.  Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.

Authors:  Camila G Moreira; Janaína K Barbiero; Deborah Ariza; Patrícia A Dombrowski; Pamela Sabioni; Mariza Bortolanza; Claudio Da Cunha; Maria A B F Vital; Marcelo M S Lima
Journal:  Neurotox Res       Date:  2011-09-28       Impact factor: 3.911

4.  Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.

Authors:  O Sader-Mazbar; Y Loboda; M J Rabey; J P M Finberg
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 5.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 6.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

Review 7.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

8.  Behavioral impairments and serotonin reductions in rats after chronic L-dopa.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

9.  The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.

Authors:  M Lagière; S Navailles; L Mignon; A Roumegous; M-F Chesselet; P De Deurwaerdère
Journal:  Exp Brain Res       Date:  2013-03-28       Impact factor: 1.972

10.  Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.

Authors:  Matteo Marti; Donata Rodi; Qin Li; Remo Guerrini; Stefania Fasano; Ilaria Morella; Alessandro Tozzi; Riccardo Brambilla; Paolo Calabresi; Michele Simonato; Erwan Bezard; Michele Morari
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.